Molnupiravir and risk of hospital admission or death in adults with covid-19: emulation of a randomized target trial using electronic health records

Emulation of a randomized target trial (n=85,998) suggests molnupiravir might have reduced hospital admission/death at 30 days in these patients in community during recent omicron predominant era (event rates 2.7% vs 3.8%, RR 0.72; 95% CI 0.64-0.79) compared with no treatment.
Source: Current Awareness Service for Health (CASH) - Category: Consumer Health News Source Type: news